Literature DB >> 14551811

Synthesis, structure analysis, solution chemistry, and in vitro insulinomimetic activity of novel oxovanadium(IV) complexes with tripodal ligands containing an imidazole group derived from amino acids.

Kenji Kawabe1, Takahiro Sasagawa, Yutaka Yoshikawa, Akio Ichimura, Katsumi Kumekawa, Naohisa Yanagihara, Toshikazu Takino, Hiromu Sakurai, Yoshitane Kojima.   

Abstract

Structures, chemical properties, and in vitro insulinomimetic activities of new vanadyl [oxovanadium(IV), VO(2+)] complexes with five tripodal ligands containing an imidazole functionality were examined. The ligands, N-(carboxymethyl)- N-(4-imidazolylmethyl)amino acids, contain glycine, ( S)- and ( R)-alanine, and ( S)- and ( R)-leucine residues. The molecular structures of the latter four alanine- and leucine-containing complexes were determined by X-ray analysis. The coordination geometry around each vanadium center was octahedral, where an imino nitrogen occupied the apical site and two carboxylate oxygens, an imidazole nitrogen, and a water molecule coordinated in the equatorial plane. The spectroscopic properties of the complexes were characterized by means of IR, electronic absorption, and CD spectra. Acid dissociation constants (p K(a)) and protonation sites of the ligands were determined by a combination of potentiometric titrations and (1)H NMR spectra. The potentiometric study demonstrated that stability constants (log beta) were not so different among the present complexes (14.0-14.9) and a species of molecular complex with a 1:1 metal:ligand ratio existed predominantly at physiological pH 7.4. EPR parameters indicated that the species at pH 7.4 had an octahedral structure similar to the complex in the solid state. On the other hand, an EPR study in phosphate buffer (pH 7.4) suggested that inorganic phosphate coordinated to the vanadium center instead of the imidazole group in the presence of excess phosphate ion. Cyclic voltammograms in the phosphate buffer showed chemically reversible oxidation waves, whereas irreversible oxidation waves were observed in non-coordinating HEPES buffer. Moreover, the oxidation potential of each complex in phosphate buffer was more positive than that in HEPES buffer. Partition coefficients of the present complexes in a n-octanol/saline system were very low, probably due to hydrophilicity of the imidazole group. The in vitro insulinomimetic activities were estimated on the basis of the ability of the complexes to inhibit epinephrine-stimulated free fatty acid release from isolated rat adipocytes. The achiral glycine-derivative complex exhibited the highest insulinomimetic activity, which was higher than that of VOSO(4) as a positive control. Putting our previous observations together, it was found that the vanadyl complexes with tetradentate amino acid derivatives having no alkyl side chain tend to have high in vitro insulinomimetic activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551811     DOI: 10.1007/s00775-003-0489-9

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  38 in total

Review 1.  Vanadium: a review of its potential role in the fight against diabetes.

Authors:  V Badmaev; S Prakash; M Majeed
Journal:  J Altern Complement Med       Date:  1999-06       Impact factor: 2.579

2.  Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats.

Authors:  H Sakurai; K Tsuchiya; M Nukatsuka; M Sofue; J Kawada
Journal:  J Endocrinol       Date:  1990-09       Impact factor: 4.286

3.  Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies.

Authors:  A B Goldfine; M E Patti; L Zuberi; B J Goldstein; R LeBlanc; E J Landaker; Z Y Jiang; G R Willsky; C R Kahn
Journal:  Metabolism       Date:  2000-03       Impact factor: 8.694

4.  In vitro study of the insulin-mimetic behaviour of vanadium(IV, V) coordination compounds.

Authors:  Dieter Rehder; João Costa Pessoa; Carlos F G C Geraldes; MargaridaM C A Castro; Themistoklis Kabanos; Tamás Kiss; Beate Meier; Giovanni Micera; Lage Pettersson; Maria Rangel; Athanasios Salifoglou; Iztok Turel; Dongren Wang
Journal:  J Biol Inorg Chem       Date:  2001-12-19       Impact factor: 3.358

5.  Glucose-lowering properties of vanadium compounds: comparison of coordination complexes with maltol or kojic acid as ligands.

Authors:  V G Yuen; P Caravan; L Gelmini; N Glover; J H McNeill; I A Setyawati; Y Zhou; C Orvig
Journal:  J Inorg Biochem       Date:  1997-11-01       Impact factor: 4.155

6.  Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus.

Authors:  G Boden; X Chen; J Ruiz; G D van Rossum; S Turco
Journal:  Metabolism       Date:  1996-09       Impact factor: 8.694

7.  Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus.

Authors:  N Cohen; M Halberstam; P Shlimovich; C J Chang; H Shamoon; L Rossetti
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

8.  A stable peroxovanadium compound with insulin-like action in human fat cells.

Authors:  J W Eriksson; P Lönnroth; B I Posner; A Shaver; C Wesslau; U P Smith
Journal:  Diabetologia       Date:  1996-02       Impact factor: 10.122

9.  Mechanism on insulin-like action of vanadyl sulfate: studies on interaction between rat adipocytes and vanadium compounds.

Authors:  M Nakai; H Watanabe; C Fujiwara; H Kakegawa; T Satoh; J Takada; R Matsushita; H Sakurai
Journal:  Biol Pharm Bull       Date:  1995-05       Impact factor: 2.233

Review 10.  The role of vanadium in the management of diabetes.

Authors:  S M Brichard; J C Henquin
Journal:  Trends Pharmacol Sci       Date:  1995-08       Impact factor: 14.819

View more
  1 in total

1.  Photoluminescence, thermal and surface properties of triarylimidazole-containing polyimide nanocomposite films.

Authors:  Wu Bai; Yunhua Lu; Zhizhi Hu; Guoyong Xiao; Hongbin Zhao; Jianmin Zhu; Zhaobin Liu
Journal:  RSC Adv       Date:  2021-11-09       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.